On May 16, the FDA granted Imdelltra an accelerated approval. In a trial with 99 study participants with symptomatic brain metastases, interstitial lung disease or non-infectious pneumonitis, the overall response rate was 40% and the median duration of response was 9.7 months.
More approvals for this indication depends on the “verification and description of clinical benefit in a confirmatory trial,” Amgen said in a news release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
